About
Green Cross continues to build on a long legacy of providing life-saving and life-sustaining specialty therapeutics. Their bioscience division began its business in 1971 as producing plasma-derived biotherapies for the first time in Korea. For more than 40 years, they have specialized in providing biotherapeutics to improve the quality of life for people with rare and serious diseases worldwide. Their vaccine business develops and produces paediatric and adult vaccine against a broad range of infectious diseases, from world’s 3rd hepatitis B vaccine to quadrivalent influenza vaccine. With their mission to improve health and well-being of people around the world, they have gone down a path that nobody wishes to explore. Their extensive research and development of innovative medicines that support treatment and prevention as well as cures for diseases in a wide range of therapeutic areas demonstrate their ongoing commitment to all people who rely on their products.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 10 investors are based in Yongin, Ch'ungch'ong-namdo, South Korea.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Yongin, South Korea
Contact Information
Find more investors like Green
Search Investors